What is Massive Bio?
Headquartered in New York City, Massive Bio operates an AI-driven platform designed to connect cancer patients and oncologists with relevant clinical trials. The company's proprietary Deep Learning Clinical Trial Matching System (DLCTMS) facilitates virtual pre-screening and patient identification, significantly reducing the friction typically associated with trial enrollment. By serving a diverse clientele that includes pharmaceutical giants, contract research organizations, and hospital networks, Massive Bio has established itself as a vital component of the modern oncology data ecosystem.
The firm's commitment to improving patient outcomes is further evidenced by its collaboration with the National Cancer Institute (NCI). Through its focus on real-world data services and site selection, Massive Bio is not merely a recruitment tool but a comprehensive infrastructure provider for the next generation of cancer research.
How much funding has Massive Bio raised?
Massive Bio has raised a total of $11.7M across 3 funding rounds:
Other Financing Round
$2.6M
Debt
$74K
Other Financing Round
$9M
Other Financing Round (2020): $2.6M with participation from Cavendish Impact Foundation and Revo Capital
Debt (2021): $74K led by PPP
Other Financing Round (2022): $9M supported by Revo Capital
Key Investors in Massive Bio
Revo Capital
Revo Capital is a venture capital firm that invests in innovative, early-stage B2B and B2C technology ventures primarily in Turkey, Eastern Europe, and the Baltics. The firm aims to empower local entrepreneurs to unlock their global potential by providing financial backing and strategic support.
Cavendish Impact Foundation
A philanthropic investment organization focused on supporting initiatives that drive social impact and healthcare innovation.
PPP
Public-Private Partnership
What's next for Massive Bio?
With the recent capital injection, Massive Bio is well-positioned to scale its AI-based trial prescreening services and expand its footprint in the global oncology market. The strategic focus will likely center on enhancing the DLCTMS capabilities and deepening partnerships with pharmaceutical enterprises to accelerate drug development timelines. As the company continues to refine its patient-centric model, it is expected to play an increasingly pivotal role in the digitization of clinical research, potentially setting new standards for trial accessibility and data-driven protocol design.
The firm's trajectory suggests a move toward broader integration within hospital networks, aiming to resolve the last-mile challenges that currently hinder clinical trial participation. By maintaining its focus on technological innovation and strategic alliances, Massive Bio is poised to remain at the forefront of the digital health revolution.
